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The highly studied p53 protein regulates multiple transitions
through the cell cycle effectively halting the growth of tumor-
like masses.[1] This gene was primitively identified an
oncogene; however, it was later derived that p53 functions
as a tumor suppressor.[1] Named due to its mass in kDa, p53
is a phosphoprotein comprised of 393 amino acids.[1] Normal
cells contain controlled, small quantities of p53 in order to
facilitate the regulation of normal cell activities such as
growth arrest, senescence, DNA repair, and apoptosis.[1,2]
Abstract
Modernizing the Approach
• Cancer remains as one of the most prevalent factors
determining the length and quality of human life.
• Exposure to carcinogens and UV radiation as well as the
complications of the ageing human body are inevitable
and often lead to cancerous tissue formations due to
abnormalities within the human body.
Methods
1. Genetic Cloning – The wild type p53 gene was isolated
and transformed into host E. coli plasmids awaiting
duplication.
2. Site-Directed Mutagenesis – The specific and intentional
placement of the mutation to the p53 gene altering the
manifestational change to the protein’s primary sequence at
leucine (L) 369 to arginine (R) 369 was induced. An example
of this process can be seen below:
Discussion
Preliminary Results
Comparisons were drawn between both DNMT1 and E2F1
due to their cellular regulatory capabilities, nucleasomal
presence, and elated tendencies for methyl transfers at
lysine sites along their respective protein chains. Similar to
p53K372, E2F1K185 is regulated by the epigenetic modifiers
SET7/9 and LSD1. Additionally, DNMT1K142 is
demethylated by LSD1.
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Current Issues
• Cancers are a large family of diseases that involve
abnormal cell growth possessing the potential to invade
other regions of the body through the formation of
neoplastic subsets.
The C-terminus domain (CTD) of p53 contains several
modifiable lysine residues that may be augmented in different
patterns resulting in an array of dissimilar protein-protein
interactions thus greatly adding to the multiplicity of functions
for the protein itself. This study aims to show that the control
of these modifications may not only reduce the causation of
multiple forms of cancers but may also be used as a
preventative mechanism by never allowing malignant masses
to have formed in the first place.
These features are pivotal the continuation of healthy cell
production. Constructively, the functions of p53 work together
to pause the cell growth cycles in order to address and repair
certain sequences of DNA if needed before cell division
commences. If repair cannot be completed, then p53 signals
for the cell to become senescent and/or later to destroy itself
via apoptosis.[1] Upon DNA damage and other cellular
stressors, the quantity of p53 is upregulated in order to
instigate either the repair or apoptotic cellular pathways;
however, continued high levels of p53 are detrimental as its
increased ability to activate the apoptotic pathway is likened
to an accelerated aging process.[1]
• Since the 2006 discovery of manipulating adult cells back
into pluripotent stem cells by Shinya Yamanaka, the
question has arisen concerning the ability to influence
cancer stem cells in a similar manner.
• The capability of reversing the effects of cancer would have
life-altering significance for medical treatment plans.
• Post-translational modification of proteins within the
nucleosome have the ability to signal and direct a significant
amount of traffic in and around the nuclei of cells. These
changes directly affect the transcription of DNA chromatin.
• Tumor protein-53 is a dominant nuclear protein capable of
multiple post-translational modifications. Understanding and
controlling tumor protein-53 will be paramount in this
strategy.
3. Transfection – Mutant L369R and wild type p53 were
inserted into human 293T liver embryonic stem cells and
reproduced in tissue cultures.
4. Western Blotting – As a check for proper transfection of
both the mutant and wild type p53 proteins, the tissue cultures
were lysed and subjected to protein-particulate size
separation. If the sample was the appropriate protein size,
further testing via attachment of specific antibodies came into
play. The secondary specific antibody was always engineered
to fluoresce resulting in evidence either for or against what
was expected. This process was repeated every time a
change in the experiment took place.
5. Small Interference RNA – Small sequences of RNA were
deliberately manufactured in order to conduct experimental
disruptions to the general functionality of both the wild type
and mutated p53 proteomes. In doing so, the analysis of
several up- and downregulations leading to hopeful answers
to the questions concerning which pathways may be either
extended or blocked in order to increase the control of cancer
stem cells and ultimately disenfranchise the bad cells and
promote the healthy ones
On one hand, when either LSD1 was inhibited or a siRNA
blocking the productions of LSD1 was introduced to proteins
E2F1 and DNMT1, the methylation of both proteins increased
which resulted in promoting the degradation pathways via E3
ubiquitin ligase proteolysis. On the other, the downregulation
of SET7/9 via siRNA eliminated methylation in the proteins
altogether. Reduction of SET7/9 stabilized the proteins with or
without the presence of LSD1. Dissimilarly, the stabilization of
WT-p53 was not specifically linked to the interplay between
LSD1 and SET7/9. We hypothesized that by mutating p53 at
leucine (L) 369 to arginine (R) that the mutant (L369R) can
now be degraded by the E3 ubiquitin ligase due to the
increased similarity of the proteasomal chain sequences of
the proteins. Results are yet to be concluded for this process.
Furthering the understanding of post-translational
modifications on p53 will provide a wealth of knowledge not
only of specific protein-protein interactions for the C-terminus
domain on the p53 protein but may lead to understanding
other nuclear proteins behaving in a similar manner. Hopefully,
extending our knowledge of the p53 proteome and its
correlating protein-protein interactions will unlock greater
realizations for many other nuclear proteins of interest.
Eventually, the idea will be to control cancer stem cells. This
power could lead to the descent of cancers as we know them.
